PPARG and Alzheimer disease: Additionally, in a clinical trial investigating the impact of the PPARγ agonist pioglitazone on mild AD patients with type II diabetes mellitus, cognitive and functional enhancements were reported, as was disease stabilization in diabetic AD patients [356].